TLXTelix Pharmaceuticals Limited
Is the business good?
Profits without cash flow. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Reports an operating profit but operating cash flow is negative, a red flag. Conversion is worsening vs a year ago.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is TLX?
Telix Pharmaceuticals Limited earns 3.5% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 5.5 points below what the capital costs: growth destroys value
- Operating margin
- 3.7%
Operating margin · Biotechnology median −82% · fiscal year to FY2025
- Cash conversion
- −0.73×
Cash conversion · 0.56× a year ago · the operating profit has not turned into cash yet
- Share count, year on year
- −2.1%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2023 | 3.3% |
| FY2024 | 11% |
| FY2025 | 3.7% |
Details›
- Gross marginfiscal year to FY2025
- 53%
- Operating marginfiscal year to FY2025
- 3.7%
- Net marginfiscal year to FY2025
- −0.89%
- Free cash flow margin
- −5.3%
- R&D as % of revenue
- 21%
- Revenue, trailing twelve months
- $804M
- Free cash flow, trailing twelve months
- −$43M
- Net income, trailing twelve months
- −$7.1M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 3.5%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry